Advanced Oncotherapy: Leveraging the modularity of LIGHT

Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly de-risked the project. Now, AVO is working on the verification and validation phase, prior to LIGHT being used on the first patients to support CE marking. At its recent investor day, the company highlighted how its differentiated business model is attracting commercial partners that should enhance long-term shareholder returns. Additionally, it is reducing the cost of PT so that it becomes accessible to all.

  • Strategy: AVO is developing a compact and modular PT system, which is affordable for the payor, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from technology know-how developed by ADAM (CERN spin-off), and relies on a world-class supplier base.
  • PT therapy: Currently, PTCOG estimates that there are 240 treatment rooms available in 97 PT centres worldwide. However, the number of treatment rooms needed by 2040 is estimated to be 10,000, which implies 20% CAGR for the next 20 years. To achieve this, costs need to be significantly reduced.
  • Attractions of LIGHT: Conventional cyclotron accelerators need to be installed into the deep sub-basement early in the construction of a PT centre. In contrast, AVO’s LIGHT system, with its linear accelerator, can be assembled into a ready-built structure. Being modular, it can be used as security in a financing deal.
  • Novel business model: Unlike conventional models which rely solely on the initial equipment sale followed by long-term service and maintenance contracts, AVO is adopting a model that combines traditional sales with customer profit-sharing arrangements, and facilitates the roll-out of technology upgrades.
  • Investment summary: After some years in development, Advanced Oncotherapy is nearing the finishing line with its first LIGHT PT system. However, the corporate goal is to have a pipeline of installations to satisfy the pent-up demand and bring down the cost of PT, thereby making this form of treatment available to many patients. The current EV only reflects the quantum of investment to get LIGHT where it is today, whereas the NPV of the cashflows from all potential sources of income from its novel business model is 214p (178p fully diluted).

DOWNLOAD THE FULL REPORT

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Advanced Oncotherapy Commercialising a breakthrough technology

    Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by achievement of a number of technical milestones,

    Hardman & Co

    Advanced Oncotherapy Preparing for commercialisation

    Advanced Oncotherapy (LON:AVO) goal is to deliver an affordable and novel proton beam therapy system (PBT), based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by the achievement of a number of

    Hardman & Co

    Advanced Oncotherapy Important regulatory milestone: ISO approval

    Advanced Oncotherapy (LON:AVO)  goal is to deliver an affordable and novel proton therapy (PT) system, based on state-of-the-art technology developed originally at the CERN. Achievement of major technical milestones has boosted confidence, and the group remains

    Hardman & Co

    Advanced Oncotherapy Four components integrated

    Advanced Oncotherapy (LON:AVO)  goal is to deliver an affordable and novel proton therapy system (PT), based on state-of-the-art technology developed originally at the world-renowned CERN. Achievement of major technical milestones has boosted confidence greatly, and the

    Advanced Oncotherapy Plc

    University Hospitals hitting mark with proton therapy

    While some proton therapy centres across the country have reportedly struggled to stay profitable, officials at University Hospitals say they’ve found the “sweet spot” two years after the Cleveland-based health system opened its own $30 million

    Advanced Oncotherapy Plc

    Advanced Oncotherapy a Significant Year

    Nicolas Serandour, CEO of Advanced Oncotherapy, said: “The technological development of our LIGHT system remains on-track and we continue to proceed with a significantly reduced overall technology risk profile. Similarly work at Harley Street remains on

    Advanced Oncotherapy Plc

    90-tonne cancer-fighting cyclotron arrives in London

    A 90-tonne piece of cancer-fighting equipment that will improve the lives of hundreds of cancer patients every year has been carefully lowered into place in its new home. The cyclotron is the size of a family

    Advanced Oncotherapy Plc

    CERN Technology Next Generation Cancer Treatment

    STFC and Advanced Oncotherapy (LON:AVO) are collaborating in the construction of a proton therapy assembly and test facility at STFC’s Daresbury Laboratory, that will build on the technology at the heart of the Large Hadron Collider

    Advanced Oncotherapy Plc

    Proton Beam therapy to come to Isarel

    The deputy Health Minister Yaakov Litzman has ordered his ministry to finalise plans to establish a Proton Beam Therapy center in Israel. The announcement came after Litzman returned to Israel this week from a visit to

    Advanced Oncotherapy Plc

    Radiation for Mesothelioma: Could Proton Therapy Be the Answer?

    Researchers at the Maryland Proton Therapy Treatment Center say that a highly-targeted version of proton beam radiation could be the future of radiotherapy for malignant plural mesothelioma. Advanced Oncotherapy (LON:AVO), is developing a unique, fully integrated,

    Advanced Oncotherapy Plc

    Professor Stephen Myers: Beams of Life

    Proton therapy is a new way of beating cancer, with fewer side effects than conventional radiation treatments, explains Stephen Myers a pioneering nuclear medicine scientist & ADAM Executive Chairman at Advanced Oncotherapy PLC (LON:AVO)   Advanced Oncotherapy

    Advanced Oncotherapy Plc

    Curing Cancer with Proton Beams

      Particle accelerators do more than just particle physics research. Suzie Sheehy takes a look at the history and promise of proton therapy: using particle accelerators to fight cancer. The discovery of X-rays in 1895 was

    Advanced Oncotherapy Plc

    Advanced Oncotherapy PLC Update on Distribution Agreement Payment

    Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the Company’s announcement of 3 April 2018, the Company has received from Yantai Cipu, through its affiliated entity Liquid

    Advanced Oncotherapy Plc

    Advanced Oncotherapy UK assembly and testing site agreement

    Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that is has signed a lease with the UK Government’s Science and Technology Facilities Council to establish a UK testing and